Biomarkers of Apoptosis
Author Information
Author(s): Ward T H, Cummings J, Dean E, Greystoke A, Hou J M, Backen A, Ranson M, Dive C
Primary Institution: University of Manchester
Conclusion
The study discusses various methodological approaches to detect biomarkers of apoptosis, emphasizing the need for panels of biomarkers to predict patient outcomes in cancer therapy.
Supporting Evidence
- Biomarkers may facilitate rational decision-making during drug discovery and in pre-clinical drug evaluation.
- Application of informative, validated biomarkers of apoptosis in clinical trials of anti-cancer therapies is urgently required.
- Panels of multiple validated biomarkers specifically tailored to particular treatment regimes or disease groups are the way forward.
Takeaway
This study talks about how scientists can find special markers in the blood that show if cancer treatments are working by looking at how cancer cells die.
Methodology
The review discusses serological assays, particularly ELISA, for detecting components of the apoptotic cascade as potential biomarkers.
Limitations
The review highlights the challenges in detecting apoptosis in vivo and the need for more comprehensive biomarker panels.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website